FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia
Laura Ondrišová(Central European Institute of Technology), Marek Mráz(Central European Institute of Technology), Eva Hoferkova(Masaryk University), Stacey M. Fernandes(Dana-Farber Cancer Institute), Václav Šeda(Central European Institute of Technology), José I. Martín‐Subero(Institució Catalana de Recerca i Estudis Avançats), Giorgia Chiodin(University of Southampton), Daniel Filip(Central European Institute of Technology), Michael Doubek(Central European Institute of Technology), Gabriela Mladonická Pavlasová(Central European Institute of Technology), Anna Panovská(Masaryk University), Stella Charalampopoulou(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ráchel Víchová(Czech Academy of Sciences, Institute of Biophysics), Matthew S. Davids(Dana-Farber Cancer Institute), Alba Maiqués-Díaz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Josef Večeřa(Masaryk University), Filip Vrbacký(Charles University), Daniel Lysák, Šárka Pospı́šilová(Central European Institute of Technology), Karla Plevová(Central European Institute of Technology), Martin Šimkovič(Charles University), Francesco Forconi(University of Leeds), Karel Souček(Czech Academy of Sciences), Jan Oppelt(Central European Institute of Technology), Krystof Hlavac(Masaryk University), Zuzana Kahounová(Czech Academy of Sciences, Institute of Biophysics), Jennifer Brown(Harvard University), Petra Pavelkova(Masaryk University), Lenka Košťálová(Central European Institute of Technology), Jiří Mayer(Central European Institute of Technology), Pedro Faria Zeni(Central European Institute of Technology)
Cited by 12
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k
Non-coding recurrent mutations in chronic lymphocytic leukaemia
|Nature|2015|851
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752